相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
S. Peters et al.
ANNALS OF ONCOLOGY (2022)
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
Corinne Faivre-Finn et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Corinne Faivre-Finn et al.
LUNG CANCER (2021)
Radiotherapy and Immunotherapy Combinations for Lung Cancer
Vishesh Agrawal et al.
CURRENT ONCOLOGY REPORTS (2021)
Comparison of Oncologic Outcomes between Carbon Ion Radiotherapy and Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Yuhei Miyasaka et al.
CANCERS (2021)
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)
Solange Peters et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
Bjørn Henning Grønberg et al.
LANCET ONCOLOGY (2021)
Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer
Francesco Fiorica et al.
CANCERS (2021)
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
Xiaoxiang Zhou et al.
LANCET ONCOLOGY (2021)
Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer
Jacopo Giuliani et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC
Yoshiaki Amino et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Proton vs photon: A model-based approach to patient selection for reduction of cardiac toxicity in locally advanced lung cancer
S. Teoh et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium
Robert T. Dess et al.
PRACTICAL RADIATION ONCOLOGY (2020)
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC
Steven H. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The abscopal effect 67 years later: from a side story to center stage
Sandra Demaria et al.
BRITISH JOURNAL OF RADIOLOGY (2020)
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study
Suresh Senan et al.
CLINICAL LUNG CANCER (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2020)
ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways
Xu Feng et al.
EMBO JOURNAL (2020)
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179
Greg A. Durm et al.
CANCER (2020)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Takahiro Yamazaki et al.
NATURE IMMUNOLOGY (2020)
Radiotherapy treatment for lung cancer: Current status and future directions
Shalini K. Vinod et al.
RESPIROLOGY (2020)
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC
James W. Welsh et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy
Dawei Chen et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
Willemijn S M E Theelen et al.
Lancet Respiratory Medicine (2020)
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
James Welsh et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
Ravindra Pramod Deshpande et al.
CANCERS (2020)
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial
David Ball et al.
LANCET ONCOLOGY (2019)
Base excision repair regulates PD-L1 expression in cancer cells
Tiara Bunga Mayang Permata et al.
ONCOGENE (2019)
Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
Ou Yamaguchi et al.
THORACIC CANCER (2019)
Prospective Study of Isolated Recurrent Tumor Re-irradiation With Carbon-Ion Beams
Katsuyuki Shirai et al.
FRONTIERS IN ONCOLOGY (2019)
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Andrea Bezjak et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S. Peters et al.
LUNG CANCER (2019)
Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer
Adnan Elhammali et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial
Joshua M. Bauml et al.
JAMA ONCOLOGY (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
Mathieu Grapin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
Kazue Yoneda et al.
BRITISH JOURNAL OF CANCER (2019)
Hypofractionated carbon-ion radiotherapy for stage I peripheral nonsmall cell lung cancer (GUNMA0701): Prospective phase II study
Jun-ichi Saitoh et al.
CANCER MEDICINE (2019)
Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer
Katsuyuki Shirai et al.
FRONTIERS IN ONCOLOGY (2019)
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System
Steven D. Criss et al.
JAMA ONCOLOGY (2019)
PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation
Megan Morisada et al.
ONCOIMMUNOLOGY (2018)
A Phase I Study of Hypofractionated Carbon-ion Radiotherapy for Stage III on-small Cell Lung Cancer
Jun-Ichi Saitoh et al.
ANTICANCER RESEARCH (2018)
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
Eric C. Ko et al.
CLINICAL CANCER RESEARCH (2018)
Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer
Chonnipa Nantavithya et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer
Zhongxing Liao et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
High linear energy transfer carbon-ion irradiation increases the release of the immune mediator high mobility group box 1 from human cancer cells
Masahiro Onishi et al.
JOURNAL OF RADIATION RESEARCH (2018)
Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer
Waqar Haque et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs
Julie M. Diamond et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
William L. Hwang et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
TIGIT: a novel immunotherapy target moving from bench to bedside
Benjamin L. Solomon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702)
Rikiya Onimaru et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Silvia C. Formenti et al.
NATURE MEDICINE (2018)
Proton therapy for small cell lung cancer
Vivek Verma et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1)
Tomoki Kimura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer
Kristin A. Higgins et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial)
Tomoki Kimura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
DNA damage-induced immune response: Micronuclei provide key platform
Nelson O. Gekara
JOURNAL OF CELL BIOLOGY (2017)
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
Stephen G. Chun et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer
Hann-Hsiang Chao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn et al.
LANCET ONCOLOGY (2017)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Shane M. Harding et al.
NATURE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
3D-structured illumination microscopy reveals clustered DNA double-strand break formation in widespread γH2AX foci after high LET heavy-ion particle radiation
Yoshihiko Hagiwara et al.
ONCOTARGET (2017)
Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients
Daichi Fujimoto et al.
SCIENTIFIC REPORTS (2017)
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer Final Results of a Phase 2 Study
Joe Y. Chang et al.
JAMA ONCOLOGY (2017)
Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study
Katsuyuki Shirai et al.
PLOS ONE (2017)
Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer
Ting Zhang et al.
SCIENTIFIC REPORTS (2017)
Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer
Jean-Claude M. Rwigema et al.
CANCER (2017)
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Kemal Catakovic et al.
CELL COMMUNICATION AND SIGNALING (2017)
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
Omar Abdel-Rahman
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Joe Y. Chang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
Jan Nyman et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
Kristina H. Young et al.
PLOS ONE (2016)
Visualization of complex DNA double-strand breaks in a tumor treated with carbon ion radiotherapy
Takahiro Oike et al.
SCIENTIFIC REPORTS (2016)
Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403
Yasushi Nagata et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation
Yuya Yoshimoto et al.
JOURNAL OF RADIATION RESEARCH (2015)
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang et al.
LANCET ONCOLOGY (2015)
Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)
Rikiya Onimaru et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer
Quynh-Nhu Nguyen et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Innate Immune Sensing and Signaling of Cytosolic Nucleic Acids
Jiaxi Wu et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study
Umberto Ricardi et al.
LUNG CANCER (2014)
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Encouse B. Golden et al.
ONCOIMMUNOLOGY (2014)
Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis
N. E. Verstegen et al.
ANNALS OF ONCOLOGY (2013)
Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery
John Varlotto et al.
CANCER (2013)
Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors
Gwendolyn H. M. J. Griffioen et al.
LUNG CANCER (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
Weiyi Peng et al.
CANCER RESEARCH (2012)
Maximizing Tumor Immunity With Fractionated Radiation
Doerthe Schaue et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Volumetric modulated arc therapy: a review of current literature and clinical use in practice
M. Teoh et al.
BRITISH JOURNAL OF RADIOLOGY (2011)
Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery
David Palma et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer
Traves D. Crabtree et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Hiroki Ishikawa et al.
NATURE (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week
Tadaaki Miyamoto et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen
Tadaaki Miyamoto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Local control and recurrence of stage I non-small cell lung cancer after carbon ion radiotherapy
M Koto et al.
RADIOTHERAPY AND ONCOLOGY (2004)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
